Ahmed Abdelmoity
Neurology with Special Qualifications in Child Neurology · Kansas City, MONPI 1992754337
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $785,683 of the $1,063,713 with a category attached, or 73.9%. Livanova USA, Inc. accounts for 72.9% of it on its own, with 14 other manufacturers making up the rest. Among neurology with special qualifications in child neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,178 payments — averaging $902.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$776K
- UCB, Inc.$73K
- Jazz Pharmaceuticals Inc.$59K
- SK Life Science, Inc.$51K
- Greenwich Biosciences, Inc.$46K
- Neurelis, Inc.$26K
- plus $32K from 9 others
Across 1 payment — averaging $15,595 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$16K
What the payments were for
- Consulting fees$66,8196%
- Speaking & faculty fees$785,68374%
- Travel & lodging$181,37817%
- Food & beverage$29,8333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 866 | $775,921 |
| UCB, Inc. | 102 | $73,352 |
| Jazz Pharmaceuticals Inc. | 56 | $58,773 |
| SK Life Science, Inc. | 55 | $51,300 |
| Greenwich Biosciences, Inc. | 46 | $46,267 |
| Neurelis, Inc. | 21 | $26,356 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $10,417 |
| Eisai Inc. | 6 | $7,520 |
| Catalyst Pharmaceuticals, Inc. | 4 | $6,186 |
| Biocodex, Inc. | 3 | $4,553 |
| UCB SA | 1 | $2,460 |
| Lundbeck LLC | 1 | $400 |
| Biomarin Pharmaceutical Inc. | 1 | $154 |
| Upsher-smith Laboratories LLC | 1 | $29 |
| Saol Therapeutics Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$466,675
- VNS Therapy$263,198
- Epidiolex$104,028
- Briviact$41,284
- XCOPRI$39,557
- VALTOCO$25,850
- Fycompa$13,684
- VNS - Sentiva$13,175
- Cenobamate$11,035
- Fintepla$10,575
- Vimpat$9,785
- DIACOMIT$4,553
- Nayzilam$4,441
- THN Sleep Therapy$3,012
- ONFI$400
- Brineura$154
- VNS - Symmetry$129
How this compares
$1,063,713 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Missouri.
See all neurology with special qualifications in child neurology providers in Missouri →
Other neurology with special qualifications in child neurology in Kansas City
- Brian AalbersKansas City$6K
- Mirza Waseem BaigKansas City$3K
- Lalit BansalKansas City$2K
- Kailash PawarKansas City$402
- Roha KhalidKansas City$327
- Miriam Baltuano SonghurstKansas City$260
- Marcie FilesKansas City$209
- Lines Vargas ColladoKansas City$180
- Jaclyn PerainoKansas City$122
- Mark GradyKansas City$84
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.